

# PLPC™ Integrated Ecosystem Investor DataRoom Demo

**“From Cell to Structure: The world’s first non-cellular immunotherapy ecosystem – ready for institutional due diligence.”**

This document provides a concise preview of the twelve master folders that compose the PLPC™ DataRoom — a structured, regulatorily verified ecosystem integrating immunotherapy (PLPC-DB™), regulatory technology (STIP™), and nutraceutical translation (PLPC-NX™). Each folder represents an independently auditable documentary unit validated under FDA Modernization Act 2.0 (NAM) standards.

## 1. DataRoom Architecture – Summary Table (45 files)

Folder Group	Scope	Main Deliverables
<b>1. Corporate &amp; Legal</b>	Ownership & Authorization	Corporate Declaration Act, Investor Engagement Letter, Due Diligence Pack
<b>2. Scientific Validation</b>	Ex vivo & RWE data	Clinical Mechanistic Dossier, Poster Series, PLPC Brochure
<b>3. Regulatory Validation</b>	NAM / 505(b)(1) readiness	Veristat & Freyr audits, STIP briefs, FDA Modernization compliance
<b>4. Financial Valuation</b>	Asset valuation USD 0.7–1.5 B	Valuation Memorandum, Benchmarks vs Juno/Kite/Flatiron
<b>5. PLPC-NX Division</b>	Nutraceutical translation	GRAS dossiers, ROI projections, BioJapan deck
<b>6. STIP™ Technology</b>	Regulatory export engine	Global regulatory pitch, NAM mapping, BioJapan validation
<b>7. UAE Strategic Context</b>	Alignment with Vision 2031–2033	Healthcare policy briefs, sovereign catalyst analysis
<b>8. Letters &amp; Audits</b>	Independent validation	Signed audit letters, regulatory equivalence matrix
<b>9. Marketing &amp; Visual Assets</b>	Investor communication	Intro deck, global pitch, corporate brochure
<b>10. Acquisition Proposal</b>	Transaction architecture	Buyer segmentation, payment models, sublicensing strategy
<b>11. Scientific Validation Files</b>	Peer-reviewed Q1 evidence	<i>Cancers 2025, Biomedicines 2025, IJMS 2025, Biology 2025</i>
<b>12. Institutional Complementary Brief</b>	Bridge module (this demo)	Executive summaries and curated annexes for initial access

## 2. How to Access the Full DataRoom

Secure preview link:

<https://app.box.com/.....>

The complete institutional DataRoom includes over 45 primary documents across 11 validated folders and this bridging module (Folder 12).

Access is granted under NDA to qualified institutional partners via the PLPC™ Executive Access Summit (Dubai).

## 3. Key Assets at a Glance

Category	Flagship Document / Publication	Reference
<b>Immunotherapy</b>	<i>Beyond Exosomes (Cancers 2025)</i>	DR.35 Evidence Base
<b>Regulatory Engine</b>	<i>STIP™ NAM Validation Pack</i>	DR.2 / DR.10
<b>Nutraceutical</b>	<i>PLPC-NX GRAS Dossier</i>	DR.23 / DR.24
<b>Financial</b>	<i>Valuation Memorandum (USD 700 M–1.5 B)</i>	DR.3c
<b>UAE Policy</b>	<i>Strategic Catalyst Assessment</i>	DR.33
<b>Marketing</b>	<i>Global Pitch Deck – PLPC World</i>	DR.18

## 4. Closing Note

*From dendritic biology to structural immunology, PLPC™ transforms immune activation into architecture. Eleven years of research, two years of global validation — delivered in a single, structured ecosystem ready for acquisition.*

Contact:

Dr. Ramón Gutiérrez-Sandoval

Chief Scientific Director | OGRD Alliance LLC

Dubai – United Arab Emirates

[csso@ogrdalliance.org](mailto:csso@ogrdalliance.org) □ [www.plpcplatform.org](http://www.plpcplatform.org)